80 results
Page 2 of 4
8-K
EX-99.1
olxj6zd
22 Nov 22
Cassava Sciences Announces $50 Million Registered Direct Offering of Common Stock
12:49pm
8-K
EX-99.2
s634o
22 Nov 22
Cassava Sciences Announces $50 Million Registered Direct Offering of Common Stock
12:49pm
424B5
2byntous g3
21 Nov 22
Prospectus supplement for primary offering
8:00am
8-K
EX-99.1
f1rdl pd3n
7 Nov 22
Cassava Sciences Reports Third Quarter Financial Results for 2022 and Business Updates
9:09am
8-K
EX-99.1
dqym760
3 Nov 22
Regulation FD Disclosure
9:26am
8-K
EX-99.1
ccy7ivx1wz
27 Oct 22
Cassava Sciences Announces Expansion of Leadership Team
4:03pm
8-K
EX-99.1
lm6are63aifui qx
3 Aug 22
Cassava Sciences Reports Second Quarter Financial Results for 2022, Mid-year Corporate Update and Interim Analysis of Open-label Study
9:25am
424B5
u6m okqxhhmfedxf86ol
29 Jul 22
Prospectus supplement for primary offering
4:15pm
8-K
EX-99.1
q96e8kns3xp f9b
5 May 22
Cassava Sciences Reports First Quarter Financial Results for 2022 and Updates on Phase 3 Clinical Program
9:04am
8-K
EX-99.1
6y9kwd f8h
28 Feb 22
Cassava Sciences Reports Full-year 2021 Financial Results and Operating Updates
12:00am
8-K
EX-99.1
o7jbv k1t6nbq
10 Nov 21
Cassava Sciences Reports Third Quarter 2021 Financial Results
9:10am
8-K
EX-99.3
ov5cvxat8z16 90kq
3 Aug 21
Regulation FD Disclosure
4:36pm
8-K
EX-99.2
zib19
3 Aug 21
Regulation FD Disclosure
4:36pm
8-K
EX-99.1
pdngl9dxwx0o
3 Aug 21
Cassava Sciences Reports Second Quarter 2021 Financial Results
8:45am